Curated News
By: NewsRamp Editorial Staff
October 05, 2026
HeartBeam Wins FDA Breakthrough Designation for At-Home Heart Attack Assessment
TLDR
- HeartBeam received FDA Breakthrough Device Designation for its heart attack assessment system, gaining prioritized review and potential expedited Medicare coverage.
- HeartBeam's 3D ECG technology collects signals from three directions to synthesize a 12-lead ECG for at-home heart attack assessment.
- HeartBeam's system aims to enable early heart attack detection at home, potentially improving outcomes and access to timely cardiac care.
- HeartBeam's FDA Breakthrough Designation for its heart attack assessment tool was granted in just 30 days, faster than the 60-day statutory review period.
Impact - Why it Matters
This news matters because heart attacks are a leading cause of death worldwide, and timely assessment is critical for survival. HeartBeam's technology could enable patients to assess heart attack symptoms at home, leading to faster medical intervention and potentially saving lives. The FDA Breakthrough Device Designation not only accelerates the review process but also opens doors to expedited Medicare coverage, which could make this life-saving technology more accessible to millions. Moreover, it represents a significant advancement in cardiac care, shifting the paradigm from hospital-based diagnostics to portable, patient-centric solutions. For investors, this milestone underscores HeartBeam's potential to disrupt the cardiac monitoring market and drive future growth.
Summary
HeartBeam (NASDAQ: BEAT), a medical technology company transforming cardiac care, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for its HeartBeam System, aimed at assessing potential heart attacks at home. This designation recognizes the potential of HeartBeam’s 3D ECG technology to enable physicians to evaluate signs of a possible heart attack when symptoms begin, regardless of the patient’s location. Notably, the FDA granted the designation within 30 days of HeartBeam's request, well ahead of the agency's 60-day statutory review period.
The Breakthrough Device Designation provides prioritized FDA review and interaction as HeartBeam advances its heart attack assessment program, and it is a prerequisite for certain expedited Medicare coverage pathways. The company plans to seek FDA alignment on the design of a multicenter pivotal study in the coming months and anticipates beginning patient enrollment shortly thereafter. If successful, the study is intended to support a future submission to expand the HeartBeam System indications to include heart attack assessment. HeartBeam’s 3D ECG technology previously received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to technology enablement.
This news was distributed by NetworkNewsWire (“NNW”), a specialized communications platform focused on financial news and content distribution. NNW is part of the Dynamic Brand Portfolio @ IBN, which offers access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more details, visit the full press release at https://nnw.fm/FxKxf.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, HeartBeam Wins FDA Breakthrough Designation for At-Home Heart Attack Assessment
